Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.45 |
| ▸ | TPMT | P51580 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6136142 | 0.90 | POLB (0.44) | CA1CA2KDM4EMAPTALDH1A1 | |
| SCHEMBL6135981 | 0.89 | PCNA (0.56) | CA1CA2KDM4ETPMTPOLB | |
| SCHEMBL6135987 | 0.87 | TSHR (0.52) | CA1CA2KDM4EMAPTALDH1A1 | |
| SCHEMBL6135844 | 0.86 | NPC1 (0.48) | CA1CA2KDM4EMAPTKMT2A | |
| SCHEMBL358548 | 0.85 | TPMT (0.54) | CA1CA2KDM4EMAPTKMT2A | |
| SCHEMBL6135835 | 0.85 | TPMT (0.58) | CA1CA2KDM4EKMT2AMEN1 | |
| SCHEMBL4431892 | 0.85 | MAPT (0.48) | CA1CA2MAPTALDH1A1TPMT | |
| SCHEMBL6136040 | 0.85 | NPBWR1 (0.49) | CA1CA2KDM4EMAPTKMT2A | |
| SCHEMBL6135858 | 0.85 | MAPT (0.47) | KDM4EMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL6136046 | 0.84 | PLK1 (0.60) | CA1CA2ALDH1A1PARP10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 708 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859615-B2 | Compounds, compositions and methods for reducing toxicity and treating or preventing diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-14 | — | — | US | claimed |
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-12-22 | — | — | US | claimed |
| EP-2331093-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | The Trustees of Columbia University in the City of New York (US) | 2011-06-15 | — | — | EP | claimed |
| US-20110124690-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-05-26 | — | — | US | claimed |
| WO-2011058367-A2 | DIAGNOSTIC TEST FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | WO | claimed |
| US-20100279327-A1 | METHOD OF TREATING DISEASES WITH PARP INHIBITORS | BIPAR SCIENCES, INC. (US) | 2010-11-04 | — | — | US | claimed |
| WO-2010025272-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-03-04 | — | — | WO | claimed |
| WO-2009105123-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-08-27 | — | — | WO | claimed |
| EP-2038654-A1 | METHOD OF TREATING DISEASES WITH PARP INHIBITORS | Bipar Sciences, Inc. (US) | 2009-03-25 | — | — | EP | claimed |
| WO-2008147418-A1 | METHOD OF TREATING DISEASES WITH PARP INHIBITORS | BIPAR SCIENCES, INC. (US) | 2008-12-04 | — | — | WO | claimed |
| US-6326402-B1 | AROMATIC ESTER COMPOUND | OCTAMER, INC. | 2001-12-04 | — | — | US | claimed |
| US-6303621-B1 | ADMINISTERING DIIODO THYRONINE ANALOGUE HAVING NO SIGNIFICANT HORMONAL ACTIVITY AND A VINCA ALKALOID SELECTED FROM LEUROSINE, VINCALEUKOBLASTINE, VINBLASTINE, LEUROFORMINE, LEUROSIDINE, LEUROCRISTINE, VINCRISTINE, DEOXY VINBLASTINE | OCTAMER, INC. | 2001-10-16 | — | — | US | claimed |
| EP-1063985-A1 | BENZOATES DERIVATIVES FOR INHIBITING ANGIOGENESIS | Biosource Technologies, Inc. (US) | 2001-01-03 | — | — | EP | claimed |
| US-6150407-A | Methods for inhibiting angiogenesis | LARGE SCALE BIOLOGY CORPORATION (US) | 2000-11-21 | — | — | US | claimed |
| EP-0954299-A4 | METHOD OF TREATING MALIGNANT TUMORS WITH THYROXINE ANALOGUES HAVING NO SIGNIFICANT HORMONAL ACTIVITY | OCTAMER INC (US) | 2000-09-06 | — | — | EP | claimed |
| WO-2000009114-A1 | METHODS FOR TREATING VIRAL INFECTIONS USING A COMPOUND CAPABLE OF INHIBITING MICROTUBULES | OCTAMER, INC. (US) | 2000-02-24 | — | — | WO | claimed |
| EP-0954299-A1 | METHOD OF TREATING MALIGNANT TUMORS WITH THYROXINE ANALOGUES HAVING NO SIGNIFICANT HORMONAL ACTIVITY | Octamer, Inc. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1999048495-A1 | BENZOATES DERIVATIVES FOR INHIBITING ANGIOGENESIS | BIOSOURCE TECHNOLOGIES, INC. (US) | 1999-09-30 | — | — | WO | claimed |
| US-5736576-A | ADMINISTERING METHYL 3,5-DIIODO-4-(4*-METHOXYPHENOXY)BENZOATE | OCTAMER, INC. (US) | 1998-04-07 | — | — | US | claimed |
| WO-1997046228-A1 | METHOD OF TREATING MALIGNANT TUMORS WITH THYROXINE ANALOGUES HAVING NO SIGNIFICANT HORMONAL ACTIVITY | OCTAMER, INC. (US) | 1997-12-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279327-A1 | METHOD OF TREATING DISEASES WITH PARP INHIBITORS | PARP3, PARP4, PARP2 | CA1 2462/4885CA2 2798/4885KDM4E 1410/4885 |
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | TUBA1C, TUBB1, TOP1 | CA1 2566/4885CA2 1751/4885KDM4E 4394/4885 |
| US-20110124690-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER | BDNF, NGF, NTRK2 | CA1 977/4885CA2 2787/4885KDM4E 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.